Bisichem Co., Ltd.

Takeda Pharmaceutical Company Limited

Cmg Pharmaceutical Co., Ltd.

Handok Inc.

Cheolhwan Yoon

Hideo Suzuki

Masaki Seto

Tsuneo Oda

Moonsoo Kim

Masato Yoshida

Hyang Choi

Shogo Marui

Tomokazu Kusumoto

Misoon Kim

Yuji Ishichi

Jae Il Lee

Jeongbeob Seo

Hyun Bin Kang

Takatoshi Yogo

Gilnam Lee

Hiroyuki Nagamiya

Hye Sun Jeon

Chul Yun Rhim

Jinwoo Lee

Kwang Ok Kim

Namhee Kim

Cheolkyu Han

Jonghwan Bae

Byungnam Kang

Inho Yang

Hongjun Kang

Sunjoo Kim

Youngdo Shin

Jungwoo Lee

Gil Nam Lee

Chaewoon Lee

Ki Nam Lee

Jay Hak Kim

Soongyu Choi

Minwoo Lee

The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of RIPK1 and the therapeutic methods.

Fused ring heteroaryl compounds as RIPK1 inhibitors

The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of ALK5 and are useful in the treatment of chronic fibrosis, vascular disorder, obesity, diabetes, autoimmune diseases and cancer.

Fused ring heteroaryl compounds and use thereof

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

Growing community of inventors

Gyeonggi-do, South Korea

Cheolhwan Yoon